Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | RET | P07949 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | LTK | P29376 | 3/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.43 |
| ▸ | CDK7 | P50613 | 3/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | GRK5 | P34947 | 2/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9413252 | 0.83 | KDR (0.56) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL17928659 | 0.76 | — | — | |
| SCHEMBL17928628 | 0.74 | — | — | |
| SCHEMBL1749423 | 0.71 | NNMT (0.33) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL12844194 | 0.71 | KDR (0.45) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL21633491 | 0.71 | KDR (0.45) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL16712838 | 0.67 | LRRK2 (0.37) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL18520344 | 0.67 | RET (0.36) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL9413248 | 0.67 | RET (0.36) | KDRRETLRRK2DAPK3PRKD3 | |
| SCHEMBL3799967 | 0.64 | NOS1 (0.66) | KDRRETLRRK2DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023154528-A1 | STEREOSELECTIVE TECHNOLOGIES FOR CHIRAL COMPOUNDS | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022125984-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200318109-A1 | LNA-G Process | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-08 | — | — | US | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| US-20170306331-A1 | ANTI-TNF COMPOUNDS | FLASHPOINT THERAPEUTICS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2017174421-A1 | BIOMARKERS FOR THE DIAGNOSIS OF INFLAMMATION-RELATED DISEASES | Universite de Bordeaux (FR) | 2017-10-12 | — | — | WO | disclosed |
| EP-2707487-B1 | RIBOSWITCHES | UNIV MANCHESTER (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20170059506-A1 | DIAGNOSTIC PRODUCTS HAVING AN ENZYME AND A STABILIZED COENZYME | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2017-03-02 | — | — | US | disclosed |
| WO-2016145102-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-20100062995-A1 | Transition state structure of human 5'methylthioadenosine phosphorylase | NATIONAL INSTITUTES OF HEALTH | 2010-03-11 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| EP-0577173-A1 | High-chloride folded tabular grain emulsions and process for their preparation | EASTMAN KODAK COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0534325-A1 | Ultrathin high chloride tabular grain emulsions | EASTMAN KODAK COMPANY (US) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200318109-A1 | LNA-G Process | OGG1, DUT, FBL | KDR 2403/4885RET 3214/4885LRRK2 3007/4885 |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | KDR 3890/4885RET 821/4885LRRK2 448/4885 |
| US-20170306331-A1 | ANTI-TNF COMPOUNDS | TNF, TNFRSF1A, POLK | KDR 2806/4885RET 4423/4885LRRK2 4353/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | KDR 3750/4885RET 4462/4885LRRK2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.